--- title: "MOTS-c Deep Research Review" slug: "mots-c" type: "research" url: "https://peptidesciencethailand.com/research/mots-c" lastReviewed: "2026-03-13" overallScore: "1.5/5" verdict: "Preclinical-promising, clinically unproven, with regulatory caution" description: "Is MOTS-c a real exercise mimetic or hype? Preclinical AMPK evidence, no human trial results, FDA + WADA flags — graded with an honest 1.5/5 verdict." --- # MOTS-c — Deep Research Review **Full name:** Mitochondrial Open Reading Frame of the 12S rRNA-c **Sequence:** MRWQEMGYIFYPRKLR **Molecular weight:** ~2174 Da (16 amino acids) **Overall evidence score:** 1.5/5 **Verdict:** Preclinical-promising, clinically unproven, with regulatory caution ## Executive Summary MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame within mitochondrial 12S rRNA, with translation proposed to occur in the cytoplasm from a polyadenylated transcript exported from mitochondria. The most robust experimental evidence base is preclinical: in cell systems and multiple mouse models, MOTS-c influences metabolic pathways linked to the folate-purine axis and AMPK activation, improves insulin sensitivity, reduces diet-induced obesity in some models, and can enhance treadmill/rotarod performance in mice. Human evidence does not currently establish MOTS-c as a therapy. Published human work is largely observational/associational (exercise-linked changes, age-linked differences in plasma vs muscle, cross-sectional disease associations), plus one large genetic association analysis of an mtDNA variant affecting the peptide sequence. These data are biologically interesting but not equivalent to clinical efficacy or safety evidence for administered MOTS-c. From a regulatory and safety standpoint, the most concrete official signals are cautionary: the U.S. FDA lists MOTS-c among bulk drug substances for compounding that may present significant safety risks, flagging potential immunogenicity/impurity and lack of identified human exposure data. WADA explicitly lists MOTS-c as an example under AMPK activators (S4.4.1), meaning it is prohibited in sport. ## Editorial Position MOTS-c is preclinical-promising with genuinely interesting mechanistic biology and strong mouse metabolic data, but it is clinically unproven in humans; observational human evidence is hypothesis-generating, not prescribing data; and regulatory/safety flags from FDA and WADA should not be downplayed. ## What It Is MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide (sequence: MRWQEMGYIFYPRKLR) encoded by a 51-bp short open reading frame in mitochondrial 12S rRNA. The foundational research argues that translation obligatorily occurs in the cytoplasm using the standard genetic code because mitochondrial translation would yield tandem start/stop codons, implying a polyadenylated transcript exported from mitochondria. It was first described in a 2015 foundational report that identified this mitochondrial-derived peptide and characterised its metabolic effects in cell systems and mouse models. ## Mechanisms ### Folate-purine axis and AMPK activation *Verdict:* Supported in cell and mouse models The most specific mechanistic pathway involves metabolic modulation through the folate-methionine cycle. In MOTS-c gain-of-function systems, metabolomics and transcriptomics showed early changes including decreased 5-methyl-THF, evidence consistent with blockade of de novo purine synthesis, and endogenous AICAR accumulation to >20-fold higher levels versus controls. AMPK phosphorylation (Thr172) increased with downstream ACC phosphorylation and CPT-1 changes, consistent with AMPK pathway activation. In mice, this translated to improved insulin sensitivity (including gold-standard clamp-based measures) and reduced diet-induced obesity signals. ### Nuclear translocation and ARE/NRF2-linked gene regulation *Verdict:* Demonstrated in cell models under stress Under metabolic stress (glucose restriction 0.5 g/L, serum deprivation 1% FBS, oxidative stress tBHP 100 uM), endogenous MOTS-c rapidly translocated to the nucleus in cell models. FITC-labelled MOTS-c (1 uM) localised to mitochondria and nucleus within 30 minutes in HEK293 cells. The research reports direct DNA binding to ARE-containing promoter fragments (e.g., HO-1, NQO1) in concentration-dependent EMSA experiments, plus stress-linked ChIP-qPCR evidence of promoter association and NRF2-linked transcriptional effects. RNA-seq supported the claim that MOTS-c can alter gene expression responses to glucose restriction in that cellular context. ## Animal Studies | Domain | Species | Dose | Outcome | Limitation | | --- | --- | --- | --- | --- | | Acute metabolic effects (normal diet) | Mouse (CD-1) | 5 mg/kg/day BID x 4 days, IP | Modest reductions in body weight, food intake, and blood glucose; some inflammatory cytokines (IL-6, TNF-alpha) reduced | Short duration; acute physiology does not equal sustained clinical effect. | | Insulin sensitivity (clamp studies) | Mouse (C57BL/6) | 5 mg/kg/day IP x 7 days | Improved glucose clearance and clamp-based measures of insulin sensitivity, including skeletal muscle glucose disposal | Short duration; mouse dosing/exposure equivalence unknown for humans. | | Diet-induced obesity prevention | Mouse (CD-1, HFD) | 0.5 mg/kg/day IP, up to 8 weeks | Prevented diet-induced obesity and hyperinsulinaemia; signals consistent with increased energy expenditure and altered substrate utilisation | Preventive model, not a therapeutic trial; does not predict human weight loss outcomes. | | Exercise performance (young mice) | Mouse (CD-1) | 5 mg/kg/day IP x 2 weeks (and 5 vs 15 mg/kg/day comparisons) | Improved rotarod performance and treadmill running capacity | Performance tests can be sensitive to multiple factors; not a human trial. | | Exercise performance (aged mice) | Mouse (C57BL/6N, 12-month and 22-month) | 15 mg/kg/day IP x 2 weeks | Improved treadmill performance in middle-aged and old mice | Short intervention; age-related mouse performance improvement does not equal human anti-ageing proof. | | Late-life intermittent dosing (lifespan) | Mouse (C57BL/6N, very old) | 15 mg/kg/day, 3x/week (late-life intermittent) | Improved physical function measures; lifespan trend reported but overall curve not significant (P=0.23); time-bounded significance point (P=0.05 until 31.8 months) | Single study; lifespan statistics not uniformly significant; cannot claim proven life extension. | | Diabetes model (NOD mice) | Mouse (NOD) | 0.5 mg/kg/day IP | Reduced islet/beta-cell senescence signals in diabetes-relevant model | Autoimmune model; not proof of human efficacy or safety. | | Tissue distribution (mdx mice) | Mouse (mdx) | 500 ug IV (single injection, rhodamine-labelled); repeated 500 ug with PMO regimens | Tissue distribution assessed; improved dystrophin expression with combination; no detectable toxicity in measured endpoints | Disease-specific context; dosing not expressed per kg; combination confounding. | ## Human Studies ### Exercise biomarker study (healthy young men) **Type:** Observational biomarker study **Participants:** 10 healthy young male volunteers **Dose:** No exogenous MOTS-c administered (endogenous measurement) **Outcome:** Exercise on stationary bicycle increased skeletal muscle MOTS-c (~11.9-fold) and circulating MOTS-c (~1.6-fold during, ~1.5-fold after exercise) **Limitations:** Small sample (n=10); measures endogenous biomarker response, not exogenous administration; does not demonstrate that giving MOTS-c improves human exercise capacity. ### Ageing biomarker divergence study **Type:** Cross-sectional observational **Participants:** Healthy ageing men (multiple age groups) **Dose:** No exogenous MOTS-c administered (endogenous measurement) **Outcome:** Circulating MOTS-c decreased with age; skeletal muscle MOTS-c ~1.5-fold higher in middle-aged and older groups vs young; associations with muscle fibre composition and quality markers **Limitations:** Cross-sectional design; cannot establish causation; age-related patterns do not prove that supplementing MOTS-c reverses ageing. ### Genetic variant K14Q and T2D association **Type:** Genetic association meta-analysis **Participants:** 27,527 participants across three cohorts **Dose:** N/A (genetic study of mtDNA variant m.1382A>C affecting MOTS-c sequence) **Outcome:** Men (not women) with the C allele showed higher T2D prevalence; association most evident in men with lowest physical activity tertile (gene-activity interaction) **Limitations:** Genetic association, not interventional. Does not constitute evidence that exogenous MOTS-c is a safe or effective treatment. ### T2D circulating levels cross-sectional comparison **Type:** Cross-sectional observational **Participants:** 45 T2D participants, 19 healthy controls **Dose:** No exogenous MOTS-c administered **Outcome:** Lower circulating MOTS-c levels in T2D group versus healthy controls **Limitations:** Associational only; lower levels could be cause, consequence, or correlated marker. Does not justify clinical claims for administered MOTS-c. ### CohBar CB4211 Phase 1a/1b (MOTS-c analogue) **Type:** Registered Phase 1a/1b RCT (NCT03998514) **Participants:** Healthy volunteers and participants with NAFLD (multiple parts) **Dose:** MOTS-c analogue CB4211; specific doses not available from public record **Outcome:** No results posted in the indexed record snapshot; company press release provides topline claims but is non-peer-reviewed **Limitations:** Registered trial without posted results or peer-reviewed publication of clinical outcomes. The existence of a registry entry is not evidence of an effective therapy. ## Hype vs Evidence | Claim | Social Media Implies | Evidence Supports | Verdict | | --- | --- | --- | --- | | MOTS-c is an exercise mimetic that boosts performance | Taking MOTS-c replaces exercise or dramatically enhances athletic performance | In mice, MOTS-c improved treadmill/rotarod outcomes under certain dosing regimens. In humans, exercise increases endogenous MOTS-c in muscle and circulation (n=10). No controlled human studies show improved VO2max, endurance, or strength from administered MOTS-c. | Preclinical signal only; prohibited in sport | | It melts fat / fixes insulin resistance | Reliable human weight loss and metabolic improvement from injecting MOTS-c | In mice, improved insulin sensitivity (gold-standard clamp data) and reduced diet-induced obesity signals. No human efficacy trials of administered MOTS-c exist. Cross-sectional human observations are not treatment proof. FDA highlights safety uncertainties for compounded MOTS-c. | Strong preclinical; no human proof | | It reprogrammes genes / activates longevity pathways | Systemic gene reprogramming and rejuvenation in humans | Cell studies show nuclear translocation under stress, RNA-seq changes, and ARE/NRF2-linked promoter interactions. Gene-expression modulation in vitro does not equal systemic reprogramming in humans. No validated human transcriptional endpoints tied to clinical benefit from dosing. | In vitro biology, not human proof | | It extends lifespan | Proven life extension in animals and humans | One mouse study reported healthspan improvements and a lifespan trend under late-life intermittent dosing, but the overall lifespan curve was not statistically significant (P=0.23). No human longevity data exist. | Trend, not established life extension | | Safe for self-use because it's natural/mitochondrial | Endogenous origin means it is inherently safe to inject | Some animal studies report no detectable toxicity under measured endpoints. FDA flags immunogenicity and impurity/characterisation risks for compounded MOTS-c and notes lack of identified human exposure data. No comprehensive human safety datasets exist. | Unsupported; safety is unknown in humans | ## Evidence Ratings | Domain | Score | Rationale | | --- | --- | --- | | Metabolic effects | 1.5/5 | Strong mechanistic evidence plus multiple mouse models with improved insulin sensitivity and reduced obesity signals. Human evidence limited to observational associations (age patterns, T2D cross-sectional). No human interventional trials. Level 3-4 evidence. | | Exercise/fitness | 1.5/5 | Mouse performance improvements across age groups and dosing regimens. Human exercise-responsive endogenous MOTS-c data (n=10). No human administration trials for exercise outcomes. Prohibited in sport as AMPK activator. Level 3-4 evidence. | | Longevity/ageing | 1/5 | Healthspan improvements in one mouse study with a lifespan trend that did not reach statistical significance overall. No human interventional longevity evidence. Level 4 evidence only. | | Safety in humans | 1/5 | Limited animal 'no overt toxicity' signals in some models. FDA explicitly flags potential immunogenicity, impurity risks, and lack of identified human exposure data for compounded MOTS-c. No comprehensive human safety datasets. Phase 1 analogue programme exists but results not posted. Level 3 observational/official caution. | ## Safety & Regulatory ### Pharmacokinetics No human pharmacokinetics or ADME data have been published for native MOTS-c. The CohBar CB4211 analogue Phase 1a/1b programme (NCT03998514) was designed to measure PK/PD, but results have not been posted in the public record. In mouse studies, MOTS-c has been administered intraperitoneally at doses ranging from 0.5 to 15 mg/kg/day, with metabolic and performance effects observed, but exposure-response relationships and bioavailability in humans are entirely unknown. Without human PK data, any dosing recommendations found online are not evidence-based. ### Safety Statement The honest safety summary is 'unknown in humans' with official concern signals around compounding, impurity, and immunogenicity. The peer-reviewed animal literature includes instances where authors report no detectable toxicity under measured endpoints, but this is not equivalent to comprehensive toxicology (reproductive toxicology, carcinogenicity, immunogenicity, long-term endocrine effects) and is not equivalent to human safety. No controlled human administration studies with safety monitoring have published results. ### Regulatory Points **U.S. FDA — Bulk drug substance with cited safety risks for compounding** FDA lists MOTS-c among bulk drug substances for compounding that may present significant safety risks, flagging potential immunogenicity risk for certain administration routes, complexities in peptide-related impurities and API characterisation, and states it has not identified human exposure data for compounded MOTS-c products and lacks important safety information. Source: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks **WADA — Prohibited (S4.4.1 AMPK activators)** WADA explicitly lists 'mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)' as an example under AMPK activators (S4.4.1), making it prohibited in sport under the category of hormone and metabolic modulators. Source: https://www.wada-ama.org/en/prohibited-list ## Open Questions / Unknowns - No controlled human trials administering MOTS-c with clinically meaningful endpoints (metabolic health, functional capacity, ageing outcomes). - No human pharmacokinetics/ADME for native MOTS-c, including exposure-response relationships, immunogenicity monitoring, and interaction profiling. - No comprehensive safety datasets beyond limited animal endpoints and beyond non-peer-reviewed reporting. - Harmonised mechanistic understanding across models (folate-purine axis vs nuclear stress signalling vs muscle stress adaptation) is lacking: which pathways matter in vivo and for which phenotypes remains unresolved. - The CohBar CB4211 analogue programme (NCT03998514) has not posted results; unpublished industry data, proprietary toxicology, and unposted trial results may exist but cannot be treated as evidence. ## Frequently Asked Questions ### What are the proven benefits of MOTS-c? MOTS-c has strong preclinical evidence in mouse models for metabolic improvements (insulin sensitivity, reduced diet-induced obesity) and exercise performance enhancement. However, no controlled human trials have been conducted with administered MOTS-c. Human evidence is limited to observational biomarker studies and genetic associations. The overall evidence score is 1.5 out of 5. ### Is MOTS-c safe? Safety in humans is unknown. The U.S. FDA lists MOTS-c among bulk drug substances for compounding that may present significant safety risks, citing potential immunogenicity, peptide impurity concerns, and lack of identified human exposure data. No comprehensive human safety datasets exist for administered MOTS-c. ### What are the side effects of MOTS-c? No human side effect profile has been established because no controlled human trials of administered MOTS-c have been completed and published. Some animal studies report no detectable toxicity within their measured endpoints, but this is not equivalent to comprehensive toxicology or human safety data. ### Is MOTS-c an exercise mimetic? In mice, MOTS-c improved treadmill and rotarod performance under certain dosing regimens. In humans, exercise increases endogenous MOTS-c in muscle and circulation (n=10 study). However, no controlled human studies show that administering MOTS-c improves VO2max, endurance, strength, or functional capacity. MOTS-c is prohibited in sport by WADA as an AMPK activator. ### Is MOTS-c legal? MOTS-c is not an approved human medicine by any major regulator. WADA explicitly lists MOTS-c as an example under AMPK activators (S4.4.1), making it prohibited in sport. The U.S. FDA flags compounded MOTS-c products as potentially presenting significant safety risks. Legal status varies by jurisdiction. ### How does MOTS-c work? Two core mechanisms are supported by peer-reviewed evidence: (1) metabolic modulation through the folate-purine axis, where MOTS-c depletes folate cycle intermediates, reduces de novo purine synthesis, accumulates AICAR (>20-fold in cell models), and activates AMPK; and (2) stress-responsive nuclear translocation, where MOTS-c enters the nucleus under metabolic stress and regulates gene expression through ARE/NRF2-linked programmes. ### Does MOTS-c extend lifespan? One mouse study reported improved physical function measures (healthspan) with late-life intermittent MOTS-c dosing and a lifespan trend, but the overall lifespan curve was not statistically significant (P=0.23). No human longevity data exist. It is not fair to claim proven life extension based on current evidence. ## References 1. **MOTS-c foundational report: metabolic effects of a mitochondrial-derived peptide** — Cell Metabolism — 2015 First description of MOTS-c as a 16-amino-acid mitochondrial-derived peptide with metabolic effects including AMPK activation, improved insulin sensitivity, and prevention of diet-induced obesity in mice https://pubmed.ncbi.nlm.nih.gov/25738459/ 2. **MOTS-c insulin sensitivity clamp studies in mice** — Cell Metabolism — 2015 Gold-standard clamp-based demonstration of improved insulin sensitivity and skeletal muscle glucose disposal with MOTS-c 5 mg/kg/day IP in C57BL/6 mice https://pubmed.ncbi.nlm.nih.gov/25738459/ 3. **MOTS-c nuclear translocation and ARE/NRF2 gene regulation under stress** — Cell Metabolism — 2018 Demonstrated stress-responsive nuclear translocation of MOTS-c with direct ARE-containing promoter binding, NRF2-linked transcriptional effects, and RNA-seq validation in cell models https://pubmed.ncbi.nlm.nih.gov/30612898/ 4. **MOTS-c physical performance and late-life regimen in mice** — Nature Communications — 2020 Improved treadmill/rotarod performance in young, middle-aged, and old mice with MOTS-c; late-life intermittent dosing improved healthspan measures with a lifespan trend https://pubmed.ncbi.nlm.nih.gov/33159052/ 5. **Exercise increases skeletal muscle and circulating MOTS-c in humans** — Nature Communications — 2020 Observational study in 10 healthy young men showing exercise-induced increases in muscle MOTS-c (~11.9-fold) and circulating MOTS-c (~1.6-fold) during stationary bicycle exercise https://pubmed.ncbi.nlm.nih.gov/33159052/ 6. **MOTS-c age-related patterns in human muscle and circulation** — Aging Cell — 2019 Cross-sectional study showing circulating MOTS-c decreases with age while skeletal muscle expression increases; associations with muscle fibre composition and quality https://pubmed.ncbi.nlm.nih.gov/30548460/ 7. **MOTS-c K14Q variant (m.1382A>C) and T2D risk in 27,527 participants** — Cell Metabolism — 2021 Meta-analysis across three cohorts showing men with the K14Q variant had higher T2D prevalence, with gene-physical activity interaction in the lowest activity tertile https://pubmed.ncbi.nlm.nih.gov/34004147/ 8. **MOTS-c and islet senescence in diabetes models** — Cell Reports Medicine — 2025 Reduced islet/beta-cell senescence in mouse diabetes models (S961, NOD) with MOTS-c; cross-sectional human comparison showing lower circulating MOTS-c in T2D vs controls https://pubmed.ncbi.nlm.nih.gov/39954685/ 9. **MOTS-c tissue distribution and dystrophin enhancement in mdx mice** — EMBO Molecular Medicine — 2022 Single IV injection rhodamine-labelled MOTS-c tissue distribution study; repeated dosing with PMO improved dystrophin expression in mdx dystrophic mice https://pubmed.ncbi.nlm.nih.gov/35315238/ 10. **CohBar CB4211 Phase 1a/1b (MOTS-c analogue) registry** — ClinicalTrials.gov — 2019 Registered randomised placebo-controlled Phase 1a/1b study of MOTS-c analogue CB4211 in healthy volunteers and NAFLD participants; no results posted https://clinicaltrials.gov/study/NCT03998514